STABLED Sub-study(AF screening)

STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study Sub-study(AF screening)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs032200054

Enrollment

600

Registered

2020-06-19

Start date

2020-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation

Interventions

Perform screening test for atrial fibrillation with Duranta(R)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Age >=20 and =<85 years at time of giving informed consent 2) Potentially Nonvalvular atrial fibrillation 3)History of ischemic stroke in previous 6 months 4)Modified Rankin Scale (mRS) =<3

Exclusion criteria

Exclusion criteria: 1)Presence of severe renal disorder(estimated creatinine clearance <30 mL/min by Cockroft-Gault equation) 2)Patient with clearly impaired heart function (ER =<35%) 3)Atrial septal defect (ASD) 4)Pregnant or possibility of pregnancy 5)Unlikely to complete the study, such as due to progressive malignant tumor 6)Participating or planning to participate in another interventional clinical trial 7)Unwilling to participate 8)Judged as incompatible for the study by the investigators

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation detection rate	—

Secondary

Measure	Time frame
> Atrial fibrillation detection time Atrial fibrillation persistence time Atrial fibrillation duration factor > Adverse events related to use of Duranta(R)	—

Contacts

Public ContactYasuhiro Nishiyama

Nippon Medical School Hospital

nomo16@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026